Table 1.
Baseline characteristic of overall study population.
| Variable | |
|---|---|
| N | 87 |
| Age (mean ± SD) | 65±14 |
| Gender. male (%) | 53 (60.9) |
| BMI> 30 kg/m2, n (%) | 15 (17.2) |
| HR (bpm) median (IQR) | 75 (47–150) |
| QRS (ms) median (IQR) | 90 (80-120) |
| I degree AV block, n (%) | 7 (7.7) |
| Smokers, n (%) | 17 (19.5) |
| AF, n (%) | 11 (12.6) |
| Dyslipidemia, n (%) | 25 (28.7) |
| Hypertension, n (%) | 58 (66.7) |
| Diabetes Mellitus, n (%) | 22 (25.3) |
| CAD, n (%) | 11 (12.6) |
| DCM, n (%) | 4 (4.6) |
| Previous ischemic stroke, n (%) | 8 (9.2) |
| CKD, n (%) | 9 (10.3) |
| COPD, n (%) | 13 (14.9) |
| Orotracheal intubation, n (%) | 16 (18.4) |
| Medical therapy: | |
| - ACEI/ARBs | 34 (39) |
| - Ca-antagonists, n (%) | 17 (19.5) |
| - Beta-blockers, n (%) | 24 (27.6) |
| - Alfa-blockers, n (%) | 4 (4.6) |
| - Amiodarone, n (%) | 3 (3.4) |
| - IC class AA drugs, n (%) | 3 (3.4) |
| - Antiplatelet drugs, n (%) | 21 (24.1) |
| - Statin, n (%) | 20 (23) |
| - Anticoagulant, n (%) | 8 (9.2) |
| - Digoxin, n (%) | 3 (3.4) |
BMI, body mass index; HR, heart rate; AV, atrio-ventricular; AF, atrial fibrillation; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DCM, dilated cardiomyopathy; ACEI, angiotensin converting enzyme inhibitor; ARBs, angiotensin II receptor blockers; AA, antiarrhythmic.